Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer
Open Access
- 18 February 2016
- journal article
- research article
- Published by Taylor & Francis in OncoImmunology
- Vol. 5 (6) , e1145333
Abstract
The infiltration of myeloid cells helps tumors to overcome immune surveillance and imparts resistance to cancer immunotherapy. Thus, strategies to modulate the effects of these immune cells may offer a potential therapeutic benefit. We report here that tasquinimod, a novel immunotherapy which targets S100A9 signaling, reduces the immunosuppressive properties of myeloid cells in preclinical models of bladder cancer (BCa). As single anticancer agent, tasquinimod treatment was effective in preventing early stage tumor growth, but did not achieve a clear antitumor effect in advanced tumors. Investigations of this response revealed that tasquinimod induces an increase in the expression of a negative regulator of T cell activation, Programmed-death-ligand 1 (PD-L1). This markedly weakens its antitumor immunity, yet provokes an “inflamed” milieu rendering tumors more prone to T cell-mediated immune attack by PD-L1 blockade. Interestingly, the combination of tasquinimod with an Anti-PD-L1 antibody enhanced the antitumor immune response in bladder tumors. This combination synergistically modulated tumor-infiltrating myeloid cells, thereby strongly affecting proliferation and activation of effector T cells. Together, our data provide insight into the rational combination of therapies that activate both innate and adaptive immune system, such as the association of S100A9-targeting agents with immune checkpoints inhibitors, to improve the response to cancer immunotherapeutic agents in BCa.Keywords
This publication has 52 references indexed in Scilit:
- T cell exclusion, immune privilege, and the tumor microenvironmentScience, 2015
- Optical In Vivo Imaging of the Alarmin S100A9 in Tumor Lesions Allows for Estimation of the Individual Malignant Potential by Evaluation of Tumor–Host Cell InteractionJournal of Nuclear Medicine, 2015
- Emerging therapeutic targets in bladder cancerCancer Treatment Reviews, 2015
- Microenvironmental regulation of tumor progression and metastasisNature Medicine, 2013
- Macrophage Regulation of Tumor Responses to Anticancer TherapiesCancer Cell, 2013
- Review of S100A9 biology and its role in cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2013
- Macrophage plasticity and polarization: in vivo veritasJournal of Clinical Investigation, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 proteinJournal of Experimental Medicine, 2008